186 related articles for article (PubMed ID: 37863080)
1. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
[TBL] [Abstract][Full Text] [Related]
2. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial.
Ong SY; Gurrin LC; Dolling L; Dixon J; Nicoll AJ; Wolthuizen M; Wood EM; Anderson GJ; Ramm GA; Allen KJ; Olynyk JK; Crawford D; Ramm LE; Gow P; Durrant S; Powell LW; Delatycki MB
Lancet Haematol; 2017 Dec; 4(12):e607-e614. PubMed ID: 29195602
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. [Recommendations of EASL clinical practice guidelines on haemochromatosis].
Tang S; Zheng SJ; Duan ZP
Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):934-938. PubMed ID: 36299186
[TBL] [Abstract][Full Text] [Related]
5. EASL Clinical Practice Guidelines on haemochromatosis.
;
J Hepatol; 2022 Aug; 77(2):479-502. PubMed ID: 35662478
[TBL] [Abstract][Full Text] [Related]
6. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
Kremyanskaya M; Kuykendall AT; Pemmaraju N; Ritchie EK; Gotlib J; Gerds A; Palmer J; Pettit K; Nath UK; Yacoub A; Molina A; Saks SR; Modi NB; Valone FH; Khanna S; Gupta S; Verstovsek S; Ginzburg YZ; Hoffman R;
N Engl J Med; 2024 Feb; 390(8):723-735. PubMed ID: 38381675
[TBL] [Abstract][Full Text] [Related]
7. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Phatak P; Brissot P; Wurster M; Adams PC; Bonkovsky HL; Gross J; Malfertheiner P; McLaren GD; Niederau C; Piperno A; Powell LW; Russo MW; Stoelzel U; Stremmel W; Griffel L; Lynch N; Zhang Y; Pietrangelo A
Hepatology; 2010 Nov; 52(5):1671-779. PubMed ID: 20814896
[TBL] [Abstract][Full Text] [Related]
8. [Genetic iron overloads and hepatic insulin-resistance iron overload syndrome: an update].
Ruivard M
Rev Med Interne; 2009 Jan; 30(1):35-42. PubMed ID: 18584923
[TBL] [Abstract][Full Text] [Related]
9. Proton Pump Inhibitors Reduce the Frequency of Phlebotomy in Patients With Hereditary Hemochromatosis.
van Aerts RM; van Deursen CT; Koek GH
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):147-52. PubMed ID: 26240005
[TBL] [Abstract][Full Text] [Related]
10. Interventions for hereditary haemochromatosis: an attempted network meta-analysis.
Buzzetti E; Kalafateli M; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011647. PubMed ID: 28273330
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
12. Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload.
Panch SR; Yau YY; West K; Diggs K; Sweigart T; Leitman SF
Transfusion; 2015 Mar; 55(3):611-22. PubMed ID: 25209879
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of 5 patients with possible primary hemochromatosis].
Jacobs EM; de Vries RA; Elving LD; Stalenhoef AF; Swinkels DW
Ned Tijdschr Geneeskd; 2003 Apr; 147(14):666-70. PubMed ID: 12712652
[TBL] [Abstract][Full Text] [Related]
14. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.
Hicken BL; Tucker DC; Barton JC
Am J Gastroenterol; 2003 Sep; 98(9):2072-7. PubMed ID: 14499790
[TBL] [Abstract][Full Text] [Related]
15. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.
Sundic T; Hervig T; Hannisdal S; Assmus J; Ulvik RJ; Olaussen RW; Berentsen S
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s84-9. PubMed ID: 24333062
[TBL] [Abstract][Full Text] [Related]
16. Hemochromatosis: Ferroptosis, ROS, Gut Microbiome, and Clinical Challenges with Alcohol as Confounding Variable.
Teschke R
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473913
[TBL] [Abstract][Full Text] [Related]
17. The role of genetic factors in patients with hepatocellular carcinoma and iron overload - a prospective series of 234 patients.
Funakoshi N; Chaze I; Alary AS; Tachon G; Cunat S; Giansily-Blaizot M; Bismuth M; Larrey D; Pageaux GP; Schved JF; Donnadieu-Rigole H; Blanc P; Aguilar-Martinez P
Liver Int; 2016 May; 36(5):746-54. PubMed ID: 26474245
[TBL] [Abstract][Full Text] [Related]
18. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women.
Roe MA; Spinks C; Heath AL; Harvey LJ; Foxall R; Wimperis J; Wolf C; Fairweather-Tait SJ
Br J Nutr; 2007 Mar; 97(3):544-9. PubMed ID: 17313717
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
